311 related articles for article (PubMed ID: 21999227)
1. The impact of subconjuctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model.
Sener E; Yuksel N; Yildiz DK; Yilmaz B; Ozdemir O; Caglar Y; Degirmenci E
Curr Eye Res; 2011 Nov; 36(11):1005-13. PubMed ID: 21999227
[TBL] [Abstract][Full Text] [Related]
2. Effects of subconjunctivally injected bevacizumab, etanercept, and the combination of both drugs on experimental corneal neovascularization.
Ozdemir O; Altintas O; Altintas L; Yildiz DK; Sener E; Caglar Y
Can J Ophthalmol; 2013 Apr; 48(2):115-20. PubMed ID: 23561605
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).
Kim TI; Kim SW; Kim S; Kim T; Kim EK
Cornea; 2008 Apr; 27(3):349-52. PubMed ID: 18362666
[TBL] [Abstract][Full Text] [Related]
4. The inhibitory effects of trastuzumab on corneal neovascularization.
Güler M; Yilmaz T; Ozercan I; Elkiran T
Am J Ophthalmol; 2009 Apr; 147(4):703-708.e2. PubMed ID: 19054498
[TBL] [Abstract][Full Text] [Related]
5. Topical and subconjunctival bevacizumab for corneal neovascularization in an experimental rat model.
Öner V; Küçükerdönmez C; Akova YA; Çolak A; Karalezli A
Ophthalmic Res; 2012; 48(3):118-23. PubMed ID: 22538642
[TBL] [Abstract][Full Text] [Related]
6. Comparative study of ranibizumab and bevacizumab on corneal neovascularization in rabbits.
Kim EK; Kong SJ; Chung SK
Cornea; 2014 Jan; 33(1):60-4. PubMed ID: 24240485
[TBL] [Abstract][Full Text] [Related]
7. Effects of subconjunctival tocilizumab versus bevacizumab in treatment of corneal neovascularization in rabbits.
Yoo AR; Chung SK
Cornea; 2014 Oct; 33(10):1088-94. PubMed ID: 25119962
[TBL] [Abstract][Full Text] [Related]
8. Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats.
Hashemian MN; Moghimi S; Kiumehr S; Riazi M; Amoli FA
Ophthalmic Res; 2009; 42(2):90-5. PubMed ID: 19546599
[TBL] [Abstract][Full Text] [Related]
9. Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs.
Hurmeric V; Mumcuoglu T; Erdurman C; Kurt B; Dagli O; Durukan AH
Cornea; 2008 Apr; 27(3):357-62. PubMed ID: 18362668
[TBL] [Abstract][Full Text] [Related]
10. Topical and subconjunctival ranibizumab (lucentis) for corneal neovascularization in experimental rat model.
Türkcü FM; Cinar Y; Türkcü G; Sahin A; Cingü AK; Yüksel H; Sahin M; Yıldırım A; Caça I
Cutan Ocul Toxicol; 2014 Jun; 33(2):138-44. PubMed ID: 23859535
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model.
Papathanassiou M; Theodossiadis PG; Liarakos VS; Rouvas A; Giamarellos-Bourboulis EJ; Vergados IA
Am J Ophthalmol; 2008 Mar; 145(3):424-431. PubMed ID: 18207123
[TBL] [Abstract][Full Text] [Related]
12. Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis.
Chen WL; Lin CT; Lin NT; Tu IH; Li JW; Chow LP; Liu KR; Hu FR
Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1659-65. PubMed ID: 18997093
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of subconjunctival and topical anti-VEGF therapy (bevacizumab) on experimental corneal neovascularization.
Ozdemir O; Altintas O; Altintas L; Ozkan B; Akdag C; Yüksel N
Arq Bras Oftalmol; 2014 Aug; 77(4):209-13. PubMed ID: 25410169
[TBL] [Abstract][Full Text] [Related]
14. The effect of subconjunctival ranibizumab on corneal and anterior segment neovascularization: study on an animal model.
Liarakos VS; Papaconstantinou D; Vergados I; Douvali M; Theodossiadis PG
Eur J Ophthalmol; 2014; 24(3):299-308. PubMed ID: 24242219
[TBL] [Abstract][Full Text] [Related]
15. Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model.
Avisar I; Weinberger D; Kremer I
Curr Eye Res; 2010 Feb; 35(2):108-15. PubMed ID: 20136420
[TBL] [Abstract][Full Text] [Related]
16. Effects of lapatinib and trastuzumab on vascular endothelial growth factor in experimental corneal neovascularization.
Kaya MK; Demir T; Bulut H; Akpolat N; Turgut B
Clin Exp Ophthalmol; 2015 Jul; 43(5):449-57. PubMed ID: 25640924
[TBL] [Abstract][Full Text] [Related]
17. The effect of subconjunctival suramin on corneal neovascularization in rabbits.
Lee HS; Chung SK
Cornea; 2010 Jan; 29(1):86-92. PubMed ID: 19907290
[TBL] [Abstract][Full Text] [Related]
18. Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats.
Hashemian MN; Z-Mehrjardi H; Moghimi S; Tahvildari M; Mojazi-Amiri H
Ophthalmic Res; 2011; 46(1):50-4. PubMed ID: 21212709
[TBL] [Abstract][Full Text] [Related]
19. The effects of subconjunctival bevacizumab, ranibizumab, and aflibercept on corneal neovascularization.
Eski MT; Teberik K; Oltulu P; Ankaralı H; Kaya M; Alpay M
Hum Exp Toxicol; 2022; 41():9603271221084674. PubMed ID: 35465742
[TBL] [Abstract][Full Text] [Related]
20. Effect of bevacizumab on corneal neovascularization in experimental rabbit model.
Ahmed A; Berati H; Nalan A; Aylin S
Clin Exp Ophthalmol; 2009 Sep; 37(7):730-6. PubMed ID: 19788671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]